The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk

Autor:	Tayo Olapo, Mary Dukic, Lisa Sershon, Bhupendra O. Khatri, Jeffery S. Garland, Joseph R. Berger, Eileen Rehn, Jean Sesing, John Kramer
Rok vydání:	2015
Předmět:	Adult Male Drug Pathology medicine.medical_specialty Dimethyl Fumarate Lymphocyte media_common.quotation_subject Young Adult chemistry.chemical_compound Multiple Sclerosis Relapsing-Remitting medicine Humans Aged Retrospective Studies media_common Aged 80 and over Dimethyl fumarate business.industry Multiple sclerosis Progressive multifocal leukoencephalopathy General Medicine Middle Aged medicine.disease CD4 Lymphocyte Count Treatment Outcome medicine.anatomical_structure Neurology chemistry Immunology Female Neurology (clinical) CD4 Lymphocyte business Immunosuppressive Agents CD8 Follow-Up Studies
Zdroj:	Multiple Sclerosis and Related Disorders. 4:377-379
ISSN:	2211-0348
DOI:	10.1016/j.msard.2015.05.003
Popis:	Dimethyl fumarate (Tecfidera™) is an effective therapy for relapsing forms of multiple sclerosis (MS). Our study suggests that this drug may have immunosuppressive properties evidenced by significant sustained reduction in CD8 lymphocyte counts and, to a lesser extent, CD4 lymphocyte counts. This observation is relevant in light of the recent case of progressive multifocal leukoencephalopathy in a patient receiving this drug.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20243096ccfb5d93d0fb5a4882756479 https://doi.org/10.1016/j.msard.2015.05.003 Zobrazit plný text záznamu Full Text from ScienceDirect